Page 9 - Dr Reddy's Laboratories

Dr Reddy's signs definitive agreement to sell its API business in Hyderabad

The business will be sold to Therapiva Pvt Ltd, a joint venture between Omnicare Drugs India and Laxai Life Sciences Private Ltd

Dr Reddy's launches cholesterol-lowering Colesevelam HCl tablets in US

Alkem Labs, Glenmark Pharmaceuticals and Impax Labs were also granted product approval to manufacture and market Colesevelam HCl tablets by the US drug regulator

Dr Reddy's seeks to revamp generics biz after remediation with USFDA flops

Sale of Bristol unit, downsizing staff, scaling down R&D and capex are some of the measures that compapny hopes will get it back to revenue growth and profitability

Dr Reddy's sells US antibiotics manufacturing facility to UAE's Neopharma

The plant and associated facilities focus on manufacturing or packaging Amoxicilin-based products, which include semi-synthetic penicillin

Pharma shares extend rally; Dr Reddy's, Sun Pharma hit 52-week high

In past 14 trading days, Nifty Pharma index outperformed the market by surging 15% as compared to 2.3% rise in Nifty 50 index.

Dr Reddy's awaiting earnings trigger; resolution of FDA-related issues must

While growth in smaller contributing geographies and stabilised sales in the US are positives, clarity on the restart of opioid treatment drug remain key to growth in earnings

Dr Reddy's lab launches Hervycta biosimilar in India for cancer treatment

BS ReporterHyderabad, 26 July: Dr Reddy's Laboratories Limited announced today that it has launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India, indicated for the treatment of certain cancers.Commenting on the launch, M V Ramana, CEO-Branded Markets at Dr Reddy's said,"We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate acess to cancer patients in India, in the oncology biosimilar space."Herceptin and its biosimilars had India sales of approximately Rs 2.90 billion for the most recent twelve months ending in December 2017, according to the company."The launch of Hervycta will immensely benefit women in India who are suffering from HER2-positive breast cancer and are in need of access to high quality, affordable innovative medicines," Raymond De Vre, senior vice president and head, Boilogics at Dr Reddy's said.---ends

Dr Reddy's slips 11% as US court prevents selling of Opioid treatment drug

The stock slipped 11% to Rs 2,070 on the NSE after the drug maker said the preliminary injunction orders issued on Friday by a US court against the company on the launch of generic Suboxone.

Dr Reddy's launches Plaquenil's generic version in US after USFDA clearance

The tablets are available in 200 mg in the bottle count sizes of 100 and 500

Dr Reddy's launches anti-epilepsy drug in US, taps into $37 mn market

The drug has been approved by the US Food and Drug Administration

US court restrains Dr Reddy's from selling generic variant of Suboxone

The court has scheduled an expedited hearing of the preliminary injection for Thursday (June 28) and a ruling is expected soon after

Dr Reddy's generic opioid addiction drug launch faces court hurdle in US

Dr Reddy's recently announced the launch of Buprenophine and Naloxone Sublingual Film, a generic equivalent of Suboxone

Dr Reddy's gains 3% on USFDA nod for launch of generic version of Suboxone

In past eight trading sessions, the stock of pharmaceutical company has rallied 20% from Rs 1,960 on June 5, 2018, as compared to 2% rise in the S&P BSE Sensex.

Dr Reddy's gains 4% as API Srikakulam plant gets USFDA clearance

The stock was up nearly 4% to Rs 2,010 on the BSE in early morning trade after the company said the US health regulator has completed the audit of its API Srikakulam plant (SEZ) with no observations.

Dr Reddy's names ex-Teva official Erez Israeli as COO, global generics head

BS ReporterHyderabad, 29 March. Dr Reddy's Laboratories Limited today announced a change in the senior leadership team. The company has appointed former president and CEO of Enzymotec, Erez Israeli as the chief operating officer and global head of generics and PSAI(pharmaceutical services and active ingredients).He will replace Abhijit Mukherjee, who is retiring on March 31, 2018 after a 15-year stint in Dr Reddy's. In a career spanning 25 years, Israeli has held leadership positions that have contributed significantly to the performance of companies he worked for, Dr Reddy's said. Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including vice president, marketing and sales for North America, vice president Asia Operations, President Teva API, group executive vice president, head of global quality, and president and CEO growth markets.Israeli will join the company on April 2. He will report to Dr Reddy's ...

Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad

The company said plant-3 at Bollaram on the city outskirts has recieved these observations upon completion of an inspection

Dr Reddy's chairman, COO added as defendants in US class action lawsuit

The company believes that the asserted claims are without merit and intends to vigorously defend itself against the allegations

Dr Reddy's Labs acquiring products but not marketing most of them

In 5 of 9 asset buys made in 2014-16, Dr Reddy's is yet to put them to use; it spent Rs 38.82 bn on the acquisitions

Dr Reddy's falls for fourth straight day on poor Q3 results

The stock was trading 3.4% lower at Rs 2,233, down 13% in past four trading days from Rs 2,562 on January 24, as compared to 0.67% decline in the S&P BSE Sensex.

Dr Reddy's Labs Q3 net profit drops 29%; Dalal Street still awaits triggers

Resolution of warning letters issued by FDA and clarity on launches key